Current Pipeline
At Isosceles, our aim is to provide an opioid alternative with access to as many patients as possible and pledge to be a part of the solution addressing unmet medical needs in postoperative pain space. This policy ensures the safety of our products through rigorous R&D testing and compliance with all FDA guidelines.
IPI201
Synthetic cannabidiol-based Intravenous injection
Acute post operative pain
Investigational drug product candidate – IPI201
Isosceles is in late-stage development with its exclusive microneedle partner to develop a dissolving microneedle capable of needle-free, intradermal delivery. Our partners have developed a sharps-free platform for vaccines that Isosceles utilizing and modifying in development of a rapid onset, site specific pain relief product.
A 2017 World Health Organization show oral cannabidiol to be only 6% bioavailable. Meaning only 6% of oral doses reach the body. IPI201 is designed to be 100% fully bioavailable and engage with the ECS to reduce cytokine inflammation.
Investigational drug product candidate - IPI301
Isosceles is in late-stage development with its exclusive microneedle partner to develop a dissolving microneedle capable of needle-free, intradermal delivery. Our partners have developed a sharps-free platform for vaccines that Isosceles utilizing and modifying in development of a rapid onset, site specific pain relief product.
